Switching from parenteral to oral formulation of ketamine in the management of severe depressive episode
-
Published:2023-06
Issue:1
Volume:2
Page:100119
-
ISSN:2773-0212
-
Container-title:Psychiatry Research Case Reports
-
language:en
-
Short-container-title:Psychiatry Research Case Reports
Author:
Jamal Sahil,
Kar Sujita KumarORCID,
Singh Amit
Reference13 articles.
1. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics;Abdallah;Annu. Rev. Med.,2015
2. A randomised add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression;Diazgranados;Arch. Gen. Psychiatry,2010
3. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder;DiazGranados;J. Clin. Psychiatry,2010
4. Development and reliability of the HAM-D/MADRS Interview: An integrated depression symptom rating scale;Iannuzzo;Psychiatry Res.,2006
5. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses;Krystal;Arch. Gen. Psychiatry,1994